Table 1.
Sensitivity of human HCC cell lines to ADI-PEG 20 and cisplatin treatment
| Cell line | ASS1 level | ADI-PEG 20 IC 50(nM) | Cisplatin IC 50(μM) |
|---|---|---|---|
| Huh7 | High | > 10a | 2.7 ± 0.3 |
| Malhavu | High | No curve | 3.3 ± 0.2 |
| Huh6 | High | No curve | 2.9 ± 0.8 |
| SNU182 | High | No curve | 1.3 ± 0.3 |
| Hep3B | High | > 10a | 0.36 ± 0.02 |
| PLC5 | High | No curve | 2.2 ± 0.3 |
| HCC36 | Medium | 2.4 ± 0.3 | 2.9 ± 1.2 |
| HepG2 | Medium | 1.4 ± 0.2 | 4.7 ± 0.4 |
| Tong | Low | 1.3 ± 0.1 | >30b |
| Sk-Hep1 | Negative | 1.1 ± 0.1 | >30b |
| SNU398 | Negative | 1.2 ± 0.1 | 23 ± 7.8 |
HCC cells were treated with various concentrations of either ADI-PEG 20 or cisplatin and the Promega luminescence assay was performed. IC50 was calculated on replicates (n = 3 to 4, mean ± SD).
aNo good IC50 fit: approximately 25-30% loss of cell viability by 10 nM ADI-PEG 20.
bNo good IC50 fit: lower limit.